Steel Grove Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Steel Grove Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-6,450	Closed	-$868K	–	316
2017 Q4	$868K	Hold	6,450	–	–	0.13%	144
2017 Q3	$943K	Sell	6,450 -2,185	-25%	-$330K	0.17%	111
2017 Q2	$1.34M	Buy	8,635 +365	+4%	+$55.8K	0.24%	87
2017 Q1	$1.2M	Hold	8,270	–	–	0.21%	90
2016 Q4	$902K	Buy	+8,270	New	+$921K	0.18%	105

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Steel Grove Capital Advisors's JAZZ Position: Q1 2018 in Review

Steel Grove Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2018, closing a stake of 6,450 shares — an estimated $868K sold.

Steel Grove Capital Advisors first reported a position in JAZZ in Q4 2016 and held it in 5 quarters. The position peaked at $1.34M in Q2 2017. 323 funds tracked by Wall St. Rank hold JAZZ as of Q1 2018.

Steel Grove Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Steel Grove Capital Advisors sold 6,450 Jazz Pharmaceuticals shares in Q1 2018, an estimated $868K.
Steel Grove Capital Advisors first reported a position in Jazz Pharmaceuticals in Q4 2016 and held it in 5 quarters.
Steel Grove Capital Advisors's Jazz Pharmaceuticals position peaked at $1.34M in Q2 2017.
323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2018.

Based on Steel Grove Capital Advisors's 13F filing for Q1 2018, filed 15 May 2018.